Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Cash from Financing Activities of -$19000.0 for Q1 2026, up 90.82% on a YoY basis from -$9957.0 in Q1 2025, and down 100.23% quarter-over-quarter from $8.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Cash from Financing Activities for 7 years, with the latest figure at -$19000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 90.82% year-over-year to -$19000.0; the trailing twelve-month figure through Mar 2026 stood at $18.0 million (up 1731.52% YoY), and the FY2025 full-year result was $17.8 million, up 1122.14% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$19000.0, down from $8.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $97.8 million in Q4 2022, with the low at -$1.4 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $6.4 million across 5 years, with a median of -$315000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 175.29% — and 2025, when it surged 4110.84%.
- Ginkgo Bioworks Holdings' Cash from Financing Activities stood at $97.8 million in 2022, then slumped by 100.65% to -$632000.0 in 2023, then jumped by 67.88% to -$203000.0 in 2024, then surged by 4110.84% to $8.1 million in 2025, then sank by 100.23% to -$19000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$19000.0 (Q1 2026), $8.1 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | 8.14 Mn |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | -98,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Dec 31, 2023 | -632,000.00 |
| Dec 31, 2023 | -632,000.00 |